• Interaction Score: 1.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ocular melanoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    23434733


    Sources:
    JAX-CKB

  • Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.88

    Interaction Types & Directionality:
    allosteric modulator
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical

  • Interaction Score: 0.44

    Interaction Types & Directionality:
    allosteric modulator
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Copanlisib + Refametinib
    Indication/Tumor Type biliary tract cancer
    Response Type sensitive


    Sources:
    JAX-CKB

  • Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    19706763


    Sources:
    JAX-CKB

  • Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ocular melanoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    23434733


    Sources:
    JAX-CKB